ClinicalTrials.gg
CompletedNCT01442038RIVER-PCIUpdated Jul 15, 2016Results posted

Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

A Phase 3 interventional study of Ranolazine and Placebo in Coronary Artery Disease and Angina Pectoris, sponsored by Gilead Sciences. Completed at 218 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-07-15.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,651
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing ranolazine in Coronary Artery Disease — none open to participants now, none under way, none of them phase 3. Ranolazine · Coronary Artery Disease.

Enrollment
Largest of 15
2,651 · median 50
Started
2011
with 3 others
Phase 3
4 of 15
none open now
Registered
7th of 15
by date
Lead sponsor
6 of 15
Gilead Sciences

Among the 15 studies testing ranolazine in Coronary Artery Disease, this one has the largest enrollment, is one of 4 that started in 2011, is one of 4 in phase 3, and was the 7th registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

None of the 15 studies testing ranolazine in Coronary Artery Disease is open now. The open studies under Coronary Artery Disease, anywhere →

About ranolazine

Ranolazine: first FDA approval 2006 (RANEXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing ranolazine in Coronary Artery Disease as a file.
02

Study summary

This study will evaluate the efficacy of ranolazine as compared with placebo when used as part of standard medical therapy in chronic angina subjects with incomplete revascularization post-percutaneous coronary intervention (PCI; formerly known as angioplasty with stent) on the composite of ischemia-driven revascularization or ischemia-driven hospitalization without revascularization.

03

Conditions studied

  • Coronary Artery Disease
  • Angina Pectoris
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written
  2. Males and females aged 18 years and older
  3. History of chronic angina defined as at least 2 episodes of anginal pain or discomfort in the chest, jaw, shoulder, back, neck, or arm that is precipitated by exertion or emotional stress, and relieved by rest or sublingual nitroglycerin, which occurred on at least 2 separate days and at least 14 days prior to PCI (in the case of staged PCI procedures, at least 14 days prior to the first PCI in the series). Participants may or may not have additional angina episodes within the 14 days prior to their first PCI in the series, as well as any time prior to Randomization.
  4. PCI for any indication (ACS or non-ACS). For the purposes of stratification at randomization, ACS will be defined as hospitalization for anginal pain or discomfort within the previous 24 hours to their hospitalization with any one (or more) of the following criteria:

    i. Elevated troponin or creatinine kinase-MB (CK-MB) consistent with myocardial infarction (MI), as reported by local laboratory and measured prior to index PCI ii. Electrocardiographic changes (including transient changes) comprising new or presumably new ST segment depression ≥ 0.1 mV (≥ 1 mm), or ST segment elevation ≥ 0.1 mV (≥ 1 mm) in at least 2 contiguous leads, or new or presumably new Left Bundle Branch Block

  5. Randomization within 14 days post-PCI. In the case of staged PCI procedures, randomization has to occur within 14 days of the last PCI in the series. Participants may be randomized starting on the day of PCI and anytime during the following 14 days. PCI is defined as an attempt to cross the lesion with a wire with the intention of performing revascularization.
  6. Post-PCI (post the last PCI for staged procedures) evidence of incomplete revascularization defined as the presence of one or more visually estimated ≥ 50% stenoses in one or more coronary arteries with reference vessel diameter of at least 2.0 mm, whether in the target vessel or in a non-target vessel regardless of the presence or absence of coronary collaterals. In the case of a participant post-coronary artery bypass grafting (CABG), incomplete revascularization is defined as the presence of one or more visually estimated ≥ 50% stenoses in an unbypassed epicardial vessel with a reference diameter of ≥ 2.0 mm, or one or more visually estimated ≥ 50% stenoses in a bypass graft supplying an otherwise unrevascularized myocardial territory.
  7. Clinically stable post-PCI. Participants randomized in-hospital on day of planned discharge or in clinic are considered stable. Participants randomized in-hospital prior to day of planned discharge must meet all of the following criteria:

    i. CK-MB \< 3 times the (ULN) at least 3 hours post-PCI, or if ≥ 3 times the ULN with evidence of decreasing CK-MB (decreased by at least 20% from the prior measurement) as reported by local laboratory. If CK-MB is not available, a participant must have evidence of normal or decreasing troponin levels (by at least 20% from the prior measurement) at least 3 hours post-PCI, as reported by local laboratory.

    ii. Systolic blood pressure ≥ 90 mm Hg and not receiving pressors or inotropes iii. No current requirement for an intra-aortic balloon pump (IABP) or any left ventricular assist device iv. No current requirement for intravenous (IV) nitroglycerin

  8. Ability and willingness to comply with all study procedures during the course of the study
  9. Females of must have a negative pregnancy test at Screening (unless surgically sterile or ) and must agree to use highly effective methods from Screening throughout the duration of study treatment and for 14 days following the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Any future planned revascularization (including staged procedures) or possible planned revascularization (ie, planned stress test to assess the imminent need for additional revascularization). Future planned stress tests for purposes of monitoring are permitted but strongly discouraged. Participants may be enrolled after the last PCI in the staged series or once a decision is made not to perform a follow up PCI, as long as Randomization occurs within 14 days from the last PCI. If a participant has had a stress test post-PCI and prior to Randomization and no further intervention is planned, the participant may be enrolled within 14 days from the last PCI.
  2. Unrevascularized left main coronary artery stenosis ≥ 50%. Participants with a history of CABG to the left coronary system will be considered to have a revascularized left main if at least one graft is patent.
  3. Major complication during or after the index PCI (in the case of staged PCI, the last in the series) including:

    i. Major bleeding (TIMI Bleeding classification or any bleeding requiring blood transfusion of ≥ 2 units of red blood cells) ii. Coronary perforation requiring treatment iii. Procedural complication requiring surgery (including CABG or peripheral vascular surgery)

  4. Stroke within 90 days prior to Randomization, or any history of stroke with permanent major neurologic disability (eg, aphasia or significant motor dysfunction)
  5. Cardiogenic shock within 90 days prior to Randomization (transient decreases in blood pressure without clinical sequelae are not considered to be cardiogenic shock)
  6. (NYHA) Class III or IV heart failure
  7. Severe renal insufficiency as assessed by an estimated \< 30 mL/min/1.73m2 using the 4 variable modification of diet in renal disease (MDRD) equation per local laboratory (based on the last available measurement prior to Randomization, collected within 1 month prior to the index PCI [in the case of staged PCI, the last in the series])
  8. Liver cirrhosis
  9. Use of Class Ia, Ic, or Class III antiarrhythmics, except for amiodarone
  10. Current treatment with strong inhibitors of
  11. Current treatment with CYP3A4 inducers or P-gp inducers
  12. Participants taking > 20 mg simvastatin daily or > 40 mg lovastatin daily who cannot reduce the dose to 20 mg once daily for simvastatin or 40 mg once daily for lovastatin, or who cannot switch to another statin
  13. Participants taking greater than a total of 1000 mg daily of metformin who cannot reduce the dose to a maximum total of 1000 mg daily (additional anti-diabetic medications may be added as clinically indicated to allow participants to decrease their metformin dose and maintain glycemic control)
  14. Previous treatment with ranolazine for > 7 consecutive days within 30 days prior to Randomization, or known or intolerance to ranolazine or to any of the
  15. Participation in another drug or investigational device study within 30 days prior to Randomization (participation in registries is allowed)
  16. Women who are pregnant or breast feeding
  17. Non-coronary artery disease comorbid conditions (eg, advanced , severe aortic stenosis) which are likely to result in death within 2 years of Randomization
  18. Any condition that in the opinion of the investigator would preclude compliance with the study protocol
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
2,651 participants (actual)

Study arms

  • Experimental
    Ranolazine

    Drug: Ranolazine

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Subjects will receive ranolazine 500 milligrams (mg) twice daily for 7 days, followed by 1000 mg administered orally twice daily for the duration of the study. Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy.

    Also known as: Ranexa

  • DrugPlacebo

    Subjects will receive one tablet of matching placebo twice daily for 7 days, followed by two tablets of matching placebo twice daily for the duration of the study. Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy.

06

What researchers measure

Primary outcomes

  1. Kaplan-Meier Estimates for Time From Randomization to First Occurrence of Ischemia-driven Revascularization or Ischemia-driven Hospitalization Without Revascularization

    Time to event distributions were estimated by the Kaplan-Meier (KM) method. 1 month = 28 days; 1 calendar year = 365 days.

    Time frame: Baseline through end of study (average 90 weeks)

Secondary outcomes

  1. Kaplan-Meier Estimates for Time From Randomization to Sudden Cardiac Death

    Time to event distributions were estimated by the Kaplan-Meier method. 1 month = 28 days; 1 calendar year = 365 days.

    Time frame: Baseline through end of study (average 90 weeks)

  2. Kaplan-Meier Estimates for Time From Randomization to Cardiovascular Death

    Time to event distributions were estimated by the Kaplan-Meier method. 1 month = 28 days; 1 calendar year = 365 days.

    Time frame: Baseline through end of study (average 90 weeks)

  3. Kaplan-Meier Estimates for Time From Randomization to Myocardial Infarction

    Time to event distributions were estimated by the Kaplan-Meier method. 1 month = 28 days; 1 calendar year = 365 days.

    Time frame: Baseline through end of study (average 90 weeks)

07

Results

Posted Jul 15, 2016

Participant flow

Participants were enrolled at study sites in the United States, Canada, Europe, Russia, and Israel. The first participant was screened on 03 November 2011. The last study visit occurred on 09 February 2015.

Participant flow — Overall Study
MilestoneRanolazinePlacebo
Started13321319
Completed10291040
Not completed303279
Withdrew: Death3529
Withdrew: Investigator-initiated early closure4443
Withdrew: Participant withdrew consent137102
Withdrew: Lost to follow-up3751
Withdrew: Adverse event2615
Withdrew: Protocol deviation920
Withdrew: Investigator's discretion1316
Withdrew: Study terminated by sponsor23

Outcome measures

PrimaryKaplan-Meier Estimates for Time From Randomization to First Occurrence of Ischemia-driven Revascularization or Ischemia-driven Hospitalization Without Revascularization

Time to event distributions were estimated by the Kaplan-Meier (KM) method. 1 month = 28 days; 1 calendar year = 365 days.

Time frame:
Baseline through end of study (average 90 weeks)
Reported as:
Number · percentage of participants
Kaplan-Meier Estimates for Time From Randomization to First Occurrence of Ischemia-driven Revascularization or Ischemia-driven Hospitalization Without Revascularization
percentage of participantsRanolazinePlacebo
KM Estimate: 1 Month3.42.3
KM Estimate: 6 Months11.310.0
KM Estimate: 12 Months19.117.3
KM Estimate: 1 Calendar Year20.218.9
KM Estimate: 18 Months23.825.3
KM Estimate: 24 Months27.629.4
KM Estimate: 2 Calendar Years30.731.0
KM Estimate: 30 months31.133.8
KM Estimate: 36 Months32.237.8
KM Estimate: 3 Calendar YearsNA37.8
Statistical analysis
  • Ranolazine vs Placebo · Cox Proportional Hazards Model · p = 0.48 (The p-value and hazard ratio are from Cox proportional hazards model stratifying by reason for qualifying percutaneous coronary intervention (PCI): acute coronary syndrome (ACS) versus non-ACS indication, and history of diabetes (yes versus no).) · Hazard ratio (hr): 0.948 · 95% CI 0.818 to 1.099
SecondaryKaplan-Meier Estimates for Time From Randomization to Sudden Cardiac Death

Time to event distributions were estimated by the Kaplan-Meier method. 1 month = 28 days; 1 calendar year = 365 days.

Time frame:
Baseline through end of study (average 90 weeks)
Reported as:
Number · percentage of participants
Kaplan-Meier Estimates for Time From Randomization to Sudden Cardiac Death
percentage of participantsRanolazinePlacebo
KM Estimate: 1 Month0.20.1
KM Estimate: 6 Months0.50.2
KM Estimate: 12 Months0.50.5
KM Estimate: 1 Calendar Year0.50.5
KM Estimate: 18 Months0.50.8
KM Estimate: 24 Months0.50.9
KM Estimate: 2 Calendar Years0.70.9
KM Estimate: 30 months0.70.9
KM Estimate: 36 Months0.70.9
KM Estimate: 3 Calendar Years0.70.9
Statistical analysis
  • Ranolazine vs Placebo · Cox Proportional Hazards Model · p = 0.40 (The p-value and hazard ratio are from Cox proportional hazards model stratifying by reason for qualifying PCI: ACS versus non-ACS indication, and history of diabetes (yes versus no).) · Hazard ratio (hr): 0.665 · 95% CI 0.244 to 1.691
SecondaryKaplan-Meier Estimates for Time From Randomization to Cardiovascular Death

Time to event distributions were estimated by the Kaplan-Meier method. 1 month = 28 days; 1 calendar year = 365 days.

Time frame:
Baseline through end of study (average 90 weeks)
Reported as:
Number · percentage of participants
Kaplan-Meier Estimates for Time From Randomization to Cardiovascular Death
percentage of participantsRanolazinePlacebo
KM Estimate: 1 Month0.20.1
KM Estimate: 6 Months0.60.4
KM Estimate: 12 Months1.00.9
KM Estimate: 1 Calendar Year1.11.0
KM Estimate: 18 Months1.51.4
KM Estimate: 24 Months1.71.7
KM Estimate: 2 Calendar Years1.91.7
KM Estimate: 30 months1.91.7
KM Estimate: 36 Months1.91.7
KM Estimate: 3 Calendar Years1.91.7
Statistical analysis
  • Ranolazine vs Placebo · Cox Proportional Hazards Model · p = 0.82 (The p-value and hazard ratio are from Cox proportional hazards model stratifying by reason for qualifying PCI: ACS versus non-ACS indication, and history of diabetes (yes versus no).) · Hazard ratio (hr): 1.073 · 95% CI 0.579 to 1.994
SecondaryKaplan-Meier Estimates for Time From Randomization to Myocardial Infarction

Time to event distributions were estimated by the Kaplan-Meier method. 1 month = 28 days; 1 calendar year = 365 days.

Time frame:
Baseline through end of study (average 90 weeks)
Reported as:
Number · percentage of participants
Kaplan-Meier Estimates for Time From Randomization to Myocardial Infarction
percentage of participantsRanolazinePlacebo
KM Estimate: 1 Month1.20.6
KM Estimate: 6 Months3.83.3
KM Estimate: 12 Months5.85.7
KM Estimate: 1 Calendar Year6.26.2
KM Estimate: 18 Months7.38.5
KM Estimate: 24 Months8.79.4
KM Estimate: 2 Calendar Years10.09.4
KM Estimate: 30 months10.910.1
KM Estimate: 36 Months10.913.4
KM Estimate: 3 Calendar Years10.913.4
Statistical analysis
  • Ranolazine vs Placebo · Cox Proportional Hazards Model · p = 0.81 (The p-value and hazard ratio are from Cox proportional hazards model stratifying by reason for qualifying PCI: ACS versus non-ACS indication, and history of diabetes (yes versus no).) · Hazard ratio (hr): 0.968 · 95% CI 0.745 to 1.256

Adverse events

Collected over Baseline through end of study drug treatment (average exposure 72 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranolazine—516/1,322 (39%)665/1,322 (50.3%)
Placebo—485/1,297 (37.4%)531/1,297 (40.9%)
Most frequent serious events
Showing 10 of 429
Most frequent serious events
EventRanolazinePlacebo
Angina pectorisCardiac disorders125/1322114/1297
Angina unstableCardiac disorders58/132271/1297
Chest painGeneral disorders37/132224/1297
Acute myocardial infarctionCardiac disorders28/132229/1297
SyncopeNervous system disorders25/132213/1297
Cardiac failure congestiveCardiac disorders20/13226/1297
Non-cardiac chest painGeneral disorders19/132219/1297
Myocardial infarctionCardiac disorders18/132218/1297
Atrial fibrillationCardiac disorders12/132214/1297
Coronary artery diseaseCardiac disorders14/132211/1297
Most frequent other events
Most frequent other events
EventRanolazinePlacebo
DizzinessNervous system disorders240/1322119/1297
ConstipationGastrointestinal disorders167/132271/1297
Angina pectorisCardiac disorders161/1322156/1297
NauseaGastrointestinal disorders123/132263/1297
FatigueGeneral disorders99/132274/1297
HeadacheNervous system disorders98/132289/1297
Chest painGeneral disorders97/132292/1297
DyspnoeaRespiratory, thoracic and mediastinal disorders89/132289/1297
CoughRespiratory, thoracic and mediastinal disorders69/132251/1297

Baseline characteristics

Safety Analysis Set: participant who were randomized and received at least one dose of study drug

Age, Continuous
Age, Continuous(years)RanolazinePlaceboTotal
Mean63.4 ± 10.5163.4 ± 10.0663.4 ± 10.29
Age, Customized
Age, Customized(participants)RanolazinePlaceboTotal
< 65 Years7147191433
65-74 Years402383785
≥ 75 Years206195401
Sex: Female, Male
Sex: Female, Male(Participants)RanolazinePlaceboTotal
Female276260536
Male104610372083
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)RanolazinePlaceboTotal
American Indian or Alaska Native033
Asian161026
Black or African American494392
Native Hawaiian or Pacific Islander213
White120311962399
Other292857
Not Permitted231639
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)RanolazinePlaceboTotal
Hispanic or Latino7264136
Not Hispanic or Latino121912082427
Not Reported282452
Unknown314
Region of Enrollment
Region of Enrollment(participants)RanolazinePlaceboTotal
Russian Federation154168322
United States499466965
United Kingdom161733
Spain8087167
Canada8085165
Austria121527
Czech Republic314475
Netherlands131326
Sweden192544
Belgium202141
Poland203172375
Italy283361
Israel111109220
France221537
Germany342761
08

Study locations

218 sites
  • Cardiology, PC
    Birmingham, Alabama 35211, United States
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Heart Center Research, LLC
    Huntsville, Alabama 35801, United States
  • Scottsdale Healthcare
    Scottsdale, Arizona 85251, United States
  • Scottsdale Healthcare
    Scottsdale, Arizona 85258, United States
  • University of California San Diego
    La Jolla, California 92037, United States
  • Spectrum Clinical Research Institute, Inc
    Moreno Valley, California 92553, United States
  • Veterans Affairs San Diego Healthcare System
    San Diego, California 92161, United States
  • John Muir Medical Center Concord Campus
    Walnut Creek, California 94598, United States
  • South Denver Cardiology Associates, PC
    Littleton, Colorado 80120, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
  • Cardiology Associates of Fairfield County, PC
    Stamford, Connecticut 06905, United States
  • Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • Zasa Clinical Research
    Atlantis, Florida 33462, United States
  • Cardiology Research Associates
    Daytona Beach, Florida 32117, United States
  • Broward General Medical Center
    Fort Lauderdale, Florida 33316, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Michigan Heart, PC
    Hialeah, Florida 33010, United States
  • Jacksonville Heart Center
    Jacksonville, Florida 32207, United States
  • University of Florida Health Sciences Center-Jacksonville
    Jacksonville, Florida 32209, United States
  • East Coast Institute for Research
    Jacksonville, Florida 32216, United States
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
  • Mount Sinai Medical Center
    Miami Beach, Florida 33140, United States
  • Florida Heart Institute
    Orlando, Florida 32803, United States
  • Cardiovascular Institute of Northwest Florida
    Panama City, Florida 32401, United States
  • Tallahassee Research Institute
    Tallahassee, Florida 32308, United States
  • Pepin Heart Hospital and Dr. Kiran C. Patel Research Institute
    Tampa, Florida 33613, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Gateway Cardiology, PC
    Jerseyville, Illinois 62052, United States
  • Indiana Heart Physicians, Inc.
    Indianapolis, Indiana 46237, United States
  • The Indiana Heart Hospital
    Indianapolis, Indiana 46250, United States
  • Northwest Indiana Cardiovascular Physicians
    Valparaiso, Indiana 46383, United States
  • Iowa Heart Center
    West De Moines, Iowa 50266, United States
  • Saint Joseph Cardiology Associates
    Lexington, Kentucky 40504, United States
  • Clinical Trials of America, Inc.
    Minden, Louisiana 71055, United States
  • Clinical Trials of America, Inc.
    Shreveport, Louisiana 71103, United States
  • Northeast Cardiology Associates
    Bangor, Maine 04401, United States
  • Baltimore Heart Associates
    Baltimore, Maryland 21215, United States
  • Union Memorial Hospital
    Baltimore, Maryland 21218, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Saint Elizabeth's Medical Center
    Boston, Massachusetts 02135, United States
  • Cape Cod Research Institute
    Hyannis, Massachusetts 02601, United States
  • Oakwood Hospital and Medical Center
    Dearborn, Michigan 48124, United States
  • Essentia Health
    Duluth, Minnesota 55805, United States
  • Minneapolis Heart Institute
    Minneapolis, Minnesota 55407, United States
  • Saint Cloud Hospital
    Saint Cloud, Minnesota 56303, United States
  • Cardiology Associates of North Mississippi
    Tupelo, Mississippi 38801, United States
  • Gateway Cardiology, PC
    Saint Louis, Missouri 63128, United States
  • Saint John's Regional Medical Center
    Springfield, Missouri 65804, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Holy Name Medical Center
    Teaneck, New Jersey 07666, United States
  • New York Methodist Hospital
    Brooklyn, New York 11215, United States
  • Buffalo Heart Group
    Buffalo, New York 14215, United States
  • SJH Cardiology Associates
    Liverpool, New York 13088, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Hudson Valley Heart Center
    Poughkeepsie, New York 12601, United States
  • Stony Brook University Medical Center
    Stony Brook, New York 11790, United States
  • Central New York Cardiology
    Utica, New York 13501, United States
  • Westchester Medical Center
    Valhalla, New York 10595, United States
  • Buffalo Cardiology and Pulmonary Associates, PC
    Williamsville, New York 14221, United States
  • Asheville Cardiology Associates
    Asheville, North Carolina 28803, United States
  • Mid Carolina Cardiology
    Charlotte, North Carolina 28204, United States
  • Veterans Affairs Medical Center, Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Carolina Cardiology Associates
    High Point, North Carolina 27262, United States
  • Wake Heart Research
    Raleigh, North Carolina 27610, United States
  • Ohio Health Research Institute
    Columbus, Ohio 43214, United States
  • Cardiology Associates of Southeast Ohio, Inc.
    Zanesville, Ohio 43701, United States
  • Oklahoma City Veterans' Affairs Medical Center
    Oklahoma City, Oklahoma 73104, United States
  • South Oklahoma Heart Research
    Oklahoma City, Oklahoma 73135, United States
  • The Heart and Vascular Center
    Beaver, Pennsylvania 15009, United States
  • Central Bucks Cardiology
    Doylestown, Pennsylvania 18901, United States
  • Saint Vincent Health Care Center
    Erie, Pennsylvania 16502, United States
  • Veterans Administration Medical Center
    Pittsburgh, Pennsylvania 15240, United States
  • Pinnacle Health System
    Wormleysburg, Pennsylvania 17043, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Research Associates of Jackson
    Jackson, Tennessee 38301, United States
  • University of Tennessee
    Knoxville, Tennessee 37920, United States
  • Centennial Heart Cardiovascular Consultants, LLC
    Nashville, Tennessee 37203, United States
  • North Texas Healthcare System, Dept. of Veteran's Affairs
    Dallas, Texas 75216, United States
  • Humble Cardiology Associates
    Humble, Texas 77338, United States
  • Gamma Medical Research Inc.
    Mission, Texas 78572, United States
  • San Antonio Endovascular and Heart Institute
    San Antonio, Texas 78258, United States
  • Victoria Heart and Vascular Center
    Victoria, Texas 77901, United States
  • Utah Cardiology, PC
    Layton, Utah 84041, United States
  • University of Vermont Medical Center, Fletcher Allen Health Care
    Burlington, Vermont 05401, United States
  • Sentara Cardiovascular Research Institute
    Norfolk, Virginia 23507, United States
  • Landesklinikum Sankt Pölten
    Saint Pölten, Lower Austria 3100, Austria
  • Landeskrankenhaus Graz West
    Graz, Styria 8020, Austria
  • Innsbruck Universitaetsklinik
    Innsbruck, Tyrol 6020, Austria
  • Allgemeines Krankenhaus der Stadt Linz
    Linz, Upper Austria 4020, Austria
  • Medizinische Universität Wien
    Wien, Vienna 1090, Austria
  • Wilhelminenspital der Stadt Wien
    Wien, Vienna 1160, Austria
  • Ziekenhuis Netwerk Antwerpen Middelheim
    Antwerp, Antwerpen 2020, Belgium
  • Imelda Ziekenhuis
    Bonheiden, Antwerpen 2820, Belgium
  • ZOL Genk, Campus Saint Jan
    Genk, Limburg 3600, Belgium
  • Algemeen Ziekenhuis Sint-Jan
    Brugge, West-Vlaanderen 8000, Belgium
  • Centre Hospitalier Universitaire Sart Tilman Liège
    Liege, 4000, Belgium
  • Royal Alexandra Hospital
    Edmonton, Alberta T5H 3V9, Canada
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • New Brunswick Heart Centre
    Saint John, New Brunswick E2L 4L2, Canada

Showing the first 100 of 218 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Weisz G, Farzaneh-Far R, Ben-Yehuda O, Debruyne B, Montalescot G, Lerman A, Mahmud E, Alexander KP, Ohman EM, White HD, Olmsted A, Walker GA, Stone GW. Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial. Am Heart J. 2013 Dec;166(6):953-959.e3. doi: 10.1016/j.ahj.2013.08.004. Epub 2013 Oct 16. PubMed 24268208 ↗
  • Weisz G, Genereux P, Iniguez A, Zurakowski A, Shechter M, Alexander KP, Dressler O, Osmukhina A, James S, Ohman EM, Ben-Yehuda O, Farzaneh-Far R, Stone GW; RIVER-PCI investigators. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Jan 9;387(10014):136-45. doi: 10.1016/S0140-6736(15)00459-6. Epub 2015 Oct 22. PubMed 26474810 ↗
  • Alexander KP, Weisz G, Prather K, James S, Mark DB, Anstrom KJ, Davidson-Ray L, Witkowski A, Mulkay AJ, Osmukhina A, Farzaneh-Far R, Ben-Yehuda O, Stone GW, Ohman EM. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial. Circulation. 2016 Jan 5;133(1):39-47. doi: 10.1161/CIRCULATIONAHA.115.019768. Epub 2015 Nov 10. PubMed 26555329 ↗
  • Fanaroff AC, Prather K, Brucker A, Wojdyla D, Davidson-Ray L, Mark DB, Williams RB, Barefoot J, Weisz G, Ben-Yehuda O, Stone GW, Ohman EM, Alexander KP. Relationship Between Optimism and Outcomes in Patients With Chronic Angina Pectoris. Am J Cardiol. 2019 May 1;123(9):1399-1405. doi: 10.1016/j.amjcard.2019.01.036. Epub 2019 Feb 7. PubMed 30771861 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2016, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2011
First posted
Sep 28, 2011
Start
Oct 2011
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Results first posted
Jul 15, 2016
Last update
Jul 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01442038
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Sep 28, 2011
Start date
Oct 2011
Primary completion
Feb 2015
Completion
Feb 2015
Results posted
Jul 15, 2016
Last update
Jul 15, 2016

Study contacts

Brian McNabb, MD
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranolazine

Start the discussion